Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > Bio Developments

Hair-raising R&D: RepliCel developing autologous cell therapy for baldness

12-Jul-2017 - Vancouver, Canada-based RepliCel is developing an autologous cell therapy to treat patients with baldness due to androgenetic alopecia. 

Spheryx awarded Ph II grant to modify tech for biologics industry

07-Jul-2017 - Spheryx, Inc. has been awarded a $1.5m grant over two years to support modifications to the company’s propriety protein aggregation detection and monitoring technology.

News in brief

French venture fund bets on Japanese microbiome firm with €11.6 m investment

05-Jul-2017 - Seventure’s Health for Life Capital fund has announced a €11.6 million ($13.2m) financing of Tokyo-based microbiome firm Anaeropharma Science.

PBL opens doors at UK bio-development centre

04-Jul-2017 - Porton Biopharma has opened a biologics characterisation and development facility at its site in the UK.

Pfizer starts work on Missouri biotherapeutics R&D hub

28-Jun-2017 - Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.

Cloud-based platform for cell therapies to meet increased production levels

28-Jun-2017 - Vineti has developed a cloud-based software platform for creating and delivering cell and gene cell therapies, which the company says is better suited to high production loads than paper-driven processes.  ...

OSE Immunotherapeutics halts recruitment in cancer vaccine trial

27-Jun-2017 - OSE Immunotherapeutics SA has halted recruitment in a Phase III trial of its cancer vaccine Tedopi (OSE2101). 

Cells held three times as long in 'delayed crosslinking' microgel tech

22-Jun-2017 - Dutch scientists have developed a microgel chip that is capable of holding single cells for analysis and research for far longer than currently available 3D culturing technologies.

Germany’s Merck invests in immune-oncology in Switzerland

21-Jun-2017 - Merck KGaA’s corporate venture division has created an immune-oncology company based on a mixture of small and large molecule drugs, including Merck and Pfizer’s Bavencio (avelumab). 

Brazilian plant to make Humira biosimilar in 'tobacco-based bioreactors'

21-Jun-2017 - A tobacco plant-based platform could make monoclonal antibodies up to 90% cheaper than mammalian systems, says Axis Biotec which is building a pilot plant in Brazil.

Cell Medica buys T cell receptor cancer candidate from UK Catapult

20-Jun-2017 - Cell Medica says it will work with the Cell and Gene Therapy Catapult to assess automation and processing technologies involved in scaling-up the acquired cancer candidate.

Aimmune to make peanut allergy candidate in Florida, US

16-Jun-2017 - Aimmune Therapeutics has opened its commercial manufacturing facility in Florida, US, where it will manufacture its investigational peanut allergy treatment.

US FDA lifts hold on Inovio's cancer vaccine trials after firm answers device questions

15-Jun-2017 - Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.

Cell line developer Selexis to be bought by JSR Life Sciences

14-Jun-2017 - JSR Life Sciences has agreed to buy cell line developer Selexis SA.

Irvine Scientific says it will build a media R&D lab at its Orange County site

14-Jun-2017 - Irvine Scientific has announced plans for an R&D centre at its site in Irvine, California citing increasing biopharma industry demand for cell culture and media regents.  


Mice in microgravity: how rodent research in space accelerates study timelines

08-Jun-2017 - Forty mice were launched into space last week aboard the SpaceX Dragon, which will deliver the genetically engineered research models to the International Space Station for study in microgravity.

Flexing one's (bispecific) Abs: Merck ups F-star deal, EpiMab contracts WuXi

07-Jun-2017 - Germany’s Merck expands its partnership with F-star and EpimAb Biotherapeutics contracts WuXi Biologics. Welcome to our round-up of bispecific antibody news.

T Cell vaccine maker TapImmune looks to monetise expression tech

07-Jun-2017 - TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.

Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy

06-Jun-2017 - Hitachi Group subsidiary PCT Cell Therapy Services will provide clinical manufacturing services for Orchard’s autologous gene therapy for the treatment of adenosine deaminase deficiency.

Patheon to manufacture amyloidosis antibody treatment for Caelum

02-Jun-2017 - Caelum Biosciences has selected Patheon to make its lead antibody CAEL-101 to treat orphan disease amyloid light-chain (AL) amyloidosis.

Merck KGaA taps Selexis cell line tech for immuno-oncology antibodies

31-May-2017 - A Merck KGaA has signed a licensing agreement for Selexis’ SUREtechnology platform and its suspension-adapted CHO-K1 cell line.

PPD expands Virginia vaccine lab with an eye on assays

24-May-2017 - Pharmaceutical Product Development LLC (PPD) has expanded its vaccine research services lab in Richmond, Virginia.

JSR Corporation invests $30m in CDMO facilities

24-May-2017 - JSR Corporation subsidiary KBI Biopharma is expanding its facilities in Durham, North Carolina and Boulder, Colorado, US, to respond to client needs.

‘Dual-warhead’ a key differentiator for ADCs, says Synaffix

17-May-2017 - Antibody-drug conjugate (ADC) technology developer Synaffix has been granted a US patent for its dual-warhead HydraSpace platform.

Norgine increases portfolio in Merus acquisition

16-May-2017 - European Norgine B.V. has agreed to acquire all issued and outstanding shares of Merus Labs International in cash for $342m (€309.6).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...